Westfield Capital Management CO LP Gilead Sciences, Inc. Transaction History

Westfield Capital Management CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$73.27 - $83.09 $153,354 - $173,907	2,093 Added 2.12%	100,981 $8.18 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $453,769 - $495,071	6,137 Added 6.62%	98,888 $7.41 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $455,375 - $519,419	5,991 Added 6.91%	92,751 $7.15 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $244,686 - $278,773	3,165 Added 3.79%	86,760 $7.2 Million
Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $290,785 - $417,467	4,666 Added 5.91%	83,595 $7.18 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $138,490 - $158,191	-2,326 Reduced 2.86%	78,929 $4.87 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $4.69 Million - $5.28 Million	81,255 New	81,255 $5.02 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

Stay updated on Westfield Capital Management CO LP with notifications on news.